Published 3 days ago • loading... • Updated 3 days ago

AbelZeta Regains Global Rights of C-CAR039 (Prizlon-cel) and Receives FDA Clearance of IND Application in Large B-cell Lymphoma

On Sunday, August 16, 2026, AbelZeta Pharma announced FDA clearance of the IND application for C-CAR039, also known as Prizloncabtagene Autoleucel, an anti-CD20/CD19 bispecific CAR-T for relapsed or refractory Large B-cell Lymphoma.
In July 2026, AbelZeta regained all development, regulatory, manufacturing, and commercialization rights for C-CAR039, positioning the company to accelerate global development of the therapy.
Data from 48 patients in China demonstrated a 91.5% overall response rate and an 85.1% complete response rate, with median progression-free survival of 60.1 months at a median follow-up of 53.9 months.
"We are pleased to welcome C-CAR039 back to our hematology malignancy portfolio," said Tony Bizuo Liu, Chairman and Chief Executive Officer of AbelZeta, noting the therapy addresses unmet needs for relapsed CAR-T patients.
AbelZeta is working with the FDA to finalize protocols for third-line and second-line Large B-cell Lymphoma patients, while a registrational Phase II clinical trial for treatment-naïve patients in China remains ongoing.

Insights by Ground AI

39 Articles

Bennington Banner

+38 Reposted by 38 other sources

Center

AbelZeta Regains Global Rights of C-CAR039 (Prizlon-cel) and Receives FDA Clearance of IND Application in Large B-cell Lymphoma

ROCKVILLE, Md. and SHANGHAI, Aug. 16, 2026 /PRNewswire/ -- AbelZeta Pharma, Inc. ("AbelZeta" or the "Company"), a global clinical-stage biopharmaceutical company focused on the discovery and development of innovative and proprietary cell-based therapeutic products, today announced that the Company received…

3 days ago

Read Full Article

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/year